1. MARKETS
  2. SECTOR : HEALTHCARE & MEDICAL EQUIPMENT SUPPLIERS
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. ACUTUS MEDICAL INC
Acutus Medical Inc XNAS: AFIB

Watchlist

Portfolio

Alert

Share
Board Meeting
The next board meeting for Acutus Medical Inc is on 04 Sep 2025 for the purpose of Acutus Medical Inc Annual General Meeting for 2025 See details


Insider Trading disclosures for Acutus Medical Inc

The latest disclosure was made by Takeo Mukai in Acutus Medical Inc where a trade of 8,475 Form 4 done at an average price of $0.2 was reported to US exchanges on March 1, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Takeo Mukai CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. 01 Mar 2024 8,475 72,874 - 0.2 1,780 Form 4
Sohn Tom SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.17 per share. 06 Feb 2024 7,582 105,009 - 0.2 1,312 Form 4
Mukai Takeo CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.19 per share. 01 Feb 2024 2,869 81,349 - 0.2 548 Form 4
Tom Sohn SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.19 per share. 01 Feb 2024 5,709 112,591 - 0.2 1,090 Form 4
Mathews Kevin SVP, Commercial Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.19 per share. 07 Jan 2024 6,342 61,106 - 0.2 1,199 Form 4
Roman H. David President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.19 per share. 07 Jan 2024 24,086 332,134 - 0.2 4,552 Form 4
Kevin Mathews SVP, Commercial Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. 05 Aug 2023 134 67,448 - 0.7 92 FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. 05 Aug 2023 433 118,300 - 0.7 299 FORM 4
Takeo Mukai CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 02 Aug 2023 501 83,447 - 0 FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Aug 2023 20,000 118,733 - 0 FORM 4
David H. Roman President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. 01 Aug 2023 6,484 356,220 - 0 FORM 4
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 24,347 - 0 FORM 4
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 25,480 25,480 - - FORM 4
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 10,920 21,840 - 0 FORM 4
David P. Bonita Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 20,822 - 0 FORM 4
David P. Bonita Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 20,972 - 0 FORM 4
Jason K. Garland Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 22,400 - 0 FORM 4
Jason K. Garland Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 20,822 - 0 FORM 4
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 8,400 20,822 - 0 FORM 4
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jun 2023 19,600 19,600 - - FORM 4
David H. Roman President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.85 per share. 01 Jun 2023 17,290 362,704 - 0.8 14,660 FORM 4
Kevin Mathews SVP, Commercial Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. 01 Apr 2023 321 66,332 - 0.8 242 FORM 4
Charlie Piscitello SVP, Chief People Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. 01 Apr 2023 855 85,683 - 0.8 645 FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. 01 Apr 2023 855 98,733 - 0.8 645 FORM 4
David H. Roman President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.75 per share. 01 Apr 2023 3,165 379,994 - 0.8 2,386 FORM 4
Kevin Mathews SVP, Commercial Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 66,653 - 0 FORM 4
Kevin Mathews SVP, Commercial Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 42,500 - - FORM 4
Charlie Piscitello SVP, Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 86,538 - 0 FORM 4
Charlie Piscitello SVP, Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 42,500 - - FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 42,500 - - FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 42,500 99,588 - 0 FORM 4
David H. Roman President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 135,000 383,159 - 0 FORM 4
David H. Roman President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 135,000 135,000 - - FORM 4
Takeo Mukai CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 47,500 47,500 - - FORM 4
Takeo Mukai CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Mar 2023 47,500 83,948 - 0 FORM 4
Kevin Mathews SVP, Commercial Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. 01 Feb 2023 3,540 24,153 - 1.9 6,620 FORM 4
Charlie Piscitello SVP, Chief People Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. 01 Feb 2023 6,627 44,038 - 1.9 12,392 FORM 4
Tom Sohn SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. 01 Feb 2023 6,525 57,190 - 1.9 12,202 FORM 4
David H. Roman President & CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. 01 Feb 2023 10,196 248,159 - 1.9 19,067 FORM 4
Takeo Mukai CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.87 per share. 01 Feb 2023 2,855 36,448 - 1.9 5,339 FORM 4
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2022 5,880 5,880 - - Stock Options (Right to Buy)
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2022 2,520 10,920 - 0 Common Stock
Jason K. Garland Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Sep 2022 32,500 32,500 - - Stock Options (Right to Buy)
Jason K. Garland Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Sep 2022 14,000 14,000 - 0 Common Stock
Takeo Mukai Interim CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Sep 2022 20,000 39,303 - 0 Common Stock
Kevin Mathews SVP, Global Sales Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.56 per share. 05 Aug 2022 134 27,693 - 1.6 209 Common Stock
Charlie Piscitello Chief People Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.56 per share. 05 Aug 2022 433 49,415 - 1.6 675 Common Stock
Tom Sohn SVP, Gen. Counsel & Secretary Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.56 per share. 05 Aug 2022 433 63,613 - 1.6 675 Common Stock
Kevin Mathews SVP, Global Sales Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 21,583 35,467 - - Employee Stock Options (Right to Buy)
Kevin Mathews SVP, Global Sales Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 20,000 57,050 - - Employee Stock Options (Right to Buy)
Kevin Mathews SVP, Global Sales Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 20,000 37,050 - - Employee Stock Options (Right to Buy)
Kevin Mathews SVP, Global Sales Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 15,647 57,050 - - Employee Stock Options (Right to Buy)
Kevin Mathews SVP, Global Sales Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 15,467 41,583 - - Employee Stock Options (Right to Buy)
Kevin Mathews SVP, Global Sales Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 21,583 57,050 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 51,418 146,740 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 51,418 95,322 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 28,022 118,718 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 28,022 146,740 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 34,800 111,940 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 34,800 146,740 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 32,500 114,240 - - Employee Stock Options (Right to Buy)
Charlie Piscitello Chief People Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 32,500 146,740 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 28,022 107,934 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 41,134 135,956 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 41,134 94,822 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 32,000 135,956 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 32,000 103,956 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 34,800 135,956 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 34,800 101,156 - - Employee Stock Options (Right to Buy)
Tom Sohn SVP, Gen. Counsel & Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 28,022 135,956 - - Employee Stock Options (Right to Buy)
David H. Roman Director, President & CEO Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 50,000 77,335 - - Employee Stock Options (Right to Buy)
David H. Roman Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 77,335 127,335 - - Employee Stock Options (Right to Buy)
David H. Roman Director, President & CEO Sale or transfer of securities back to the company at price $ 0.00 per share. 25 Jul 2022 77,335 50,000 - - Employee Stock Options (Right to Buy)
David H. Roman Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 75,000 258,355 - 0 Common Stock
David H. Roman Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 50,000 127,335 - - Employee Stock Options (Right to Buy)
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 15,947 - 0 Common Stock
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 8,400 - 0 Common Stock
R. Scott Huennekens Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
David P. Bonita Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
David P. Bonita Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 12,422 - 0 Common Stock
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 12,572 - 0 Common Stock
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 12,422 - 0 Common Stock
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 19,600 19,600 - - Stock Options (Right to Buy)
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 8,400 12,422 - 0 Common Stock
David H. Roman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 100,000 183,355 - 0 Common Stock
Vincent J. Burgess Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. 01 Apr 2022 3,896 61,469 - 1.3 5,065 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. 01 Apr 2022 733 45,844 - 1.3 953 Common Stock
David H. Roman Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. 01 Apr 2022 3,248 83,355 - 1.3 4,222 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2022 32,000 46,577 - 0 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2022 32,000 32,000 - - Stock Options (Right to Buy)
David H. Roman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2022 50,000 86,603 - 0 Common Stock
David H. Roman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2022 50,000 50,000 - - Stock Options (Right to Buy)
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Aug 2021 15,191 15,191 - - Stock Options (Right to Buy)
Niamh Pellegrini Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Aug 2021 4,172 4,172 - 0 Common Stock
Vincent J. Burgess Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.52 per share. 05 Aug 2021 1,922 65,365 - 15.5 29,829 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.52 per share. 05 Aug 2021 305 14,577 - 15.5 4,734 Common Stock
David P. Bonita Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 14.00 per share. 19 Jul 2021 714,285 4,872,025 - 14 9,999,990 Common Stock
David P. Bonita Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 14.00 per share. 19 Jul 2021 357,143 1,677,361 - 14 5,000,002 Common Stock
Shahzad Malik Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 7,022 7,022 - - Stock Options (Right to Buy)
Shahzad Malik Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 1,800 4,022 - 0 Common Stock
David P. Bonita Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 1,800 4,022 - 0 Common Stock
David P. Bonita Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 7,022 7,022 - - Stock Options (Right to Buy)
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 1,800 4,022 - 0 Common Stock
Andrew ElBardissi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 7,022 7,022 - - Stock Options (Right to Buy)
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 7,022 7,022 - - Stock Options (Right to Buy)
Shaden Marzouk Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jun 2021 1,800 4,022 - 0 Common Stock
Vincent J. Burgess Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 158,691 158,691 - - Stock Options (Right to Buy)
Vincent J. Burgess Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 45,065 67,287 - 0 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 9,882 14,882 - 0 Common Stock
Steven McQuillan SVP, Clinical Affairs & QA Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 34,800 34,800 - - Stock Options (Right to Buy)
David H. Roman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 36,603 36,603 - 0 Common Stock
David H. Roman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Apr 2021 77,335 77,335 - - Stock Options (Right to Buy)
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Mar 2021 3,147 7,547 - 0 Common Stock
John F. Sheridan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Mar 2021 10,882 10,882 - - Stock Options (Right to Buy)
Shahzad Malik None 10 Aug 2020 171,695 0 - - Series D Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 34,261 0 - - Series B Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 254,495 0 - - Series A Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 10,738 0 - - Series A Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 1,551,713 1,551,713 - 0 Common Stock
Shahzad Malik None 10 Aug 2020 65,436 65,436 - 0 Common Stock
Shahzad Malik None 10 Aug 2020 812,683 0 - - Series B Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 13,195 0 - - Series C Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 312,840 0 - - Series C Convertible Preferred Stock
Shahzad Malik None 10 Aug 2020 7,242 0 - - Series D Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 3,784,240 4,157,740 - 0 Common Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 378,733 0 - - Series D Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 1,202,117 0 - - Series D Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 389,116 0 - - Series D Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 899,985 0 - - Series C Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 647,582 0 - - Series C Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 673,123 0 - - Series B Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 872,302 0 - - Series B Convertible Preferred Stock
David P. Bonita Director, Ten Percent Owner 10 Aug 2020 1,278,718 1,320,218 - 0 Common Stock
David P. Bonita Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 18.00 per share. 10 Aug 2020 41,500 41,500 - 18 747,000 Common Stock
David P. Bonita Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 18.00 per share. 10 Aug 2020 373,500 373,500 - 18 6,723,000 Common Stock
John Barnickel Chief Commercial Officer Purchase of securities on an exchange or from another person at price $ 18.00 per share. 10 Aug 2020 7,300 13,966 - 18 131,400 Common Stock
Vincent J. Burgess Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 22,222 22,222 - 0 Common Stock
Vincent J. Burgess Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 124,542 124,542 - - Stock Options (Right to Buy)
Shahzad Malik None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 2,222 2,222 - 0 Common Stock
Shahzad Malik None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 12,454 12,454 - - Stock Options (Right to Buy)
David P. Bonita None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 2,222 2,222 - 0 Common Stock
David P. Bonita None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 12,454 12,454 - - Stock Options (Right to Buy)
Gary W. Doherty Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 28,022 28,022 - - Stock Options (Right to Buy)
Gary W. Doherty Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 5,000 5,000 - 0 Common Stock
John Barnickel Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 6,666 6,666 - 0 Common Stock
John Barnickel Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 153,569 153,569 - - Stock Options (Right to Buy)
Andrew ElBardissi None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 2,222 2,222 - 0 Common Stock
Andrew ElBardissi None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 12,454 12,454 - - Stock Options (Right to Buy)
Shaden Marzouk None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 2,222 2,222 - 0 Common Stock
Shaden Marzouk None Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Aug 2020 12,454 12,454 - - Stock Options (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters